Ritchie Natalie D, Baucom Katherine J W, Sauder Katherine A
Ambulatory Care Services, Denver Health and Hospital Authority, Denver, CO, USA.
Department of Psychiatry, University of Colorado School of Medicine, Aurora, CO, USA.
Diabetes Metab Syndr Obes. 2020 Aug 19;13:2949-2957. doi: 10.2147/DMSO.S218334. eCollection 2020.
To address the public health and economic burden of type 2 diabetes, the Centers for Disease Control and Prevention (CDC) began dissemination of the National Diabetes Prevention Program (NDPP) in the United States in 2010. Based on the intensive lifestyle intervention from a large efficacy trial, the NDPP aims to reduce incidence through lifestyle change and weight loss. This narrative review summarizes evidence on reach, effectiveness, and sustainability of the NDPP, while highlighting opportunities to overcome challenges in these areas. Major successes include reaching hundreds of thousands of at-risk individuals across the nation, with notable effectiveness upon full participation and widespread insurance coverage. Yet, more work is needed to ensure greater public health impact, particularly among priority populations at heightened risk who also experience disparities in program outcomes. Preliminary evidence suggests a number of strategies may improve reach and effectiveness of the NDPP, often with more rigorous study needed prior to widespread uptake. Updating the NDPP to better match the current evidence-base may also be important, such as directly targeting glycemia with a patient-centered approach and promoting metformin as an adjunct or second-line treatment. Finally, revisiting pay-for-performance reimbursement models may be critical to sustainability by ensuring adequate availability of suppliers and ultimately reducing diabetes prevalence.
为应对2型糖尿病带来的公共卫生和经济负担,美国疾病控制与预防中心(CDC)于2010年开始在美国推广国家糖尿病预防计划(NDPP)。基于一项大型疗效试验中的强化生活方式干预,NDPP旨在通过改变生活方式和减轻体重来降低发病率。本叙述性综述总结了关于NDPP的覆盖范围、有效性和可持续性的证据,同时强调了克服这些领域挑战的机会。主要成就包括在全国范围内惠及数十万高危个体,在充分参与和广泛的保险覆盖下取得了显著成效。然而,仍需开展更多工作以确保对公共卫生产生更大影响,特别是在风险更高且在项目成果方面存在差异的重点人群中。初步证据表明,一些策略可能会提高NDPP的覆盖范围和有效性,但在广泛采用之前通常需要更严格的研究。更新NDPP以更好地匹配当前的证据基础也可能很重要,例如以患者为中心的方法直接针对血糖,并推广二甲双胍作为辅助或二线治疗。最后,重新审视绩效付费报销模式对于可持续性可能至关重要,通过确保供应商的充足供应并最终降低糖尿病患病率。